MX2022013147A - Anticuerpos anti-interleucina 31 de acción prolongada para uso veterinario. - Google Patents
Anticuerpos anti-interleucina 31 de acción prolongada para uso veterinario.Info
- Publication number
- MX2022013147A MX2022013147A MX2022013147A MX2022013147A MX2022013147A MX 2022013147 A MX2022013147 A MX 2022013147A MX 2022013147 A MX2022013147 A MX 2022013147A MX 2022013147 A MX2022013147 A MX 2022013147A MX 2022013147 A MX2022013147 A MX 2022013147A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- long
- acting anti
- veterinary use
- acting
- Prior art date
Links
- 101001043821 Homo sapiens Interleukin-31 Proteins 0.000 abstract 3
- 102100021596 Interleukin-31 Human genes 0.000 abstract 3
- 241000282465 Canis Species 0.000 abstract 2
- 241000282324 Felis Species 0.000 abstract 2
- 241000283073 Equus caballus Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se proporcionan varias modalidades relacionadas con anticuerpos anti-IL31 de acción prolongada que se unen a IL31 canina y/o IL31 felina; dichos anticuerpos pueden usarse en métodos para tratar afecciones inducidas por IL31 en animales de compañía, como caninos, felinos y equinos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063014033P | 2020-04-22 | 2020-04-22 | |
US202063014549P | 2020-04-23 | 2020-04-23 | |
PCT/US2021/028548 WO2021216810A1 (en) | 2020-04-22 | 2021-04-22 | Long-acting anti-il31 antibodies for veterinary use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022013147A true MX2022013147A (es) | 2023-02-09 |
Family
ID=78269992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022013147A MX2022013147A (es) | 2020-04-22 | 2021-04-22 | Anticuerpos anti-interleucina 31 de acción prolongada para uso veterinario. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230312702A1 (es) |
EP (1) | EP4138914A4 (es) |
JP (1) | JP2023524643A (es) |
KR (1) | KR20230005875A (es) |
CN (1) | CN115666644A (es) |
AU (1) | AU2021258198A1 (es) |
BR (1) | BR112022021216A2 (es) |
CA (1) | CA3173864A1 (es) |
MX (1) | MX2022013147A (es) |
WO (1) | WO2021216810A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10093731B2 (en) * | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY195714A (en) * | 2008-04-11 | 2023-02-07 | Chugai Pharmaceutical Co Ltd | Antigen-Binding Molecule Capable of Binding to Two or More Antigen Molecules Repeatedly |
WO2018073185A1 (en) * | 2016-10-17 | 2018-04-26 | Vetoquinol Sa | Modified antibody constant region |
US10093731B2 (en) * | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
WO2018156367A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
EP3765500A2 (en) * | 2018-03-16 | 2021-01-20 | Zoetis Services LLC | Interleukin-31 monoclonal antibodies for veterinary use |
US20210388053A1 (en) * | 2018-10-18 | 2021-12-16 | Kindred Biosciences, Inc. | Fc Variants with Altered Binding to Neonatal Fc Receptor (FCRN) for Veterinary Use |
US11542333B2 (en) * | 2019-01-03 | 2023-01-03 | Invetx, Inc. | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
US20240067738A1 (en) * | 2020-03-18 | 2024-02-29 | Elanco Us Inc. | Anti-il4 receptor antibodies for veterinary use |
-
2021
- 2021-04-22 EP EP21792891.0A patent/EP4138914A4/en active Pending
- 2021-04-22 MX MX2022013147A patent/MX2022013147A/es unknown
- 2021-04-22 JP JP2022563136A patent/JP2023524643A/ja active Pending
- 2021-04-22 CA CA3173864A patent/CA3173864A1/en active Pending
- 2021-04-22 BR BR112022021216A patent/BR112022021216A2/pt unknown
- 2021-04-22 AU AU2021258198A patent/AU2021258198A1/en active Pending
- 2021-04-22 WO PCT/US2021/028548 patent/WO2021216810A1/en unknown
- 2021-04-22 KR KR1020227039975A patent/KR20230005875A/ko active Search and Examination
- 2021-04-22 US US17/996,557 patent/US20230312702A1/en active Pending
- 2021-04-22 CN CN202180036332.3A patent/CN115666644A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4138914A4 (en) | 2024-05-22 |
WO2021216810A1 (en) | 2021-10-28 |
CA3173864A1 (en) | 2021-10-28 |
KR20230005875A (ko) | 2023-01-10 |
US20230312702A1 (en) | 2023-10-05 |
JP2023524643A (ja) | 2023-06-13 |
BR112022021216A2 (pt) | 2022-12-06 |
EP4138914A1 (en) | 2023-03-01 |
AU2021258198A1 (en) | 2022-11-17 |
CN115666644A (zh) | 2023-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018254542A1 (en) | IL4/IL13 receptor molecule for veterinary use | |
MX2021004313A (es) | Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario. | |
MX2021002971A (es) | Anticuerpos del receptor anti-interleucina 4 para uso veterinario. | |
ATE384433T1 (de) | Kauspielzeug für tiere | |
AR096671A1 (es) | Método para preparar una composición de aditivos para alimento para animales | |
MX2022002360A (es) | Anticuerpos de anti-il31 para uso veterinario. | |
MX2021011335A (es) | Antagonistas de ngf para uso medicinal. | |
MX362713B (es) | Métodos y sistemas de alimentación para animales jóvenes del ganado usando compuestos sensitivos. | |
MX2022013147A (es) | Anticuerpos anti-interleucina 31 de acción prolongada para uso veterinario. | |
MX2022013149A (es) | Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario. | |
MX2009005965A (es) | Composiciones de alimento para animales. | |
PH12014502423B1 (en) | Treatment of poultry, pigs or fish for reducing the feed conversion ratio or increasing their bodyweight gain | |
MX2022011335A (es) | Anticuerpos del receptor anti-interleucina 4 para uso veterinario. | |
MX2021013826A (es) | Mezcla nutricional a base de mct para proporcionar beneficios para la salud en animales. | |
MX2021015590A (es) | Metodos y composiciones con beneficios renales para felinos. | |
Sinclair et al. | Behaviour of isolated piglets before and after tooth clipping, grinding or sham-grinding | |
Henriksen et al. | What is the best feeding strategy to adjust female minks’ body condition without compromising the welfare during the winter season? | |
Wallenbeck et al. | Effect of sire on pig leg health in commercial organic herds | |
Seyoum et al. | Prevalence of workrelated wound and associated risk factors in cart mules of adet town, north-western Ethiopia | |
Van den Broeke et al. | Interaction of immunocastration and sex on performance, carcass and meat quality in pigs | |
UA39273U (ru) | Способ консолидации продуктивных и племенных признаков сумского типа украинской черно-пестрой молочной породы | |
Campler | The effect of housing on dairy cattle behavior during the transition period | |
Wilkins | African Queens | |
Anneberg | Farm workers’ perception of animal welfare–A Danish Study | |
Forsberg et al. | The Belgian Shepherd’s tale genome-wide study across 9 dog breeds reveals an association of fructosamine concentration to a locus in Belgian Shepherds |